The US FDA has approved a new treatment option– ciltacabtagene autoleucel (cilta-cel)– for patients with refractory or relapsed multiple myeloma and who have already tried four or more therapies. The new drug, marketed as Carvykti by Janssen and Legend Biotech, is a chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA), and a new target for therapies for multiple myeloma.

Source: medscape